ArriVent BioPharma, Inc.

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

AVBP$13.49-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2025 and 2024

BALANCE SHEETS


· · December 31,
· · 2025 · · 2024
Assets · · · ·
Current assets: · · · ·
Cash and cash equivalents	$45,540	$74,293
Short-term investments	267,281	144,570
Prepaid expenses and other current assets	20,076	8,116
Total current assets	332,897	226,979
Long-term investments	—	47,683
Right of use assets – operating leases	13	154
Deferred offering costs	69	—
Other assets	190	126
Total assets	$333,169	$274,942

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$5,934	$3,782
Accrued expenses	19,997	13,330
Operating lease liabilities	14	162
Total current liabilities	25,945	17,274
Operating lease liabilities, net of current amount	—	14
Total liabilities	25,945	17,288

Commitments and contingencies (Note 7)

Stockholders’ equity:
Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock $0.0001 par value, 200,000,000 shares authorized; 42,452,251 and 33,706,765 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	4	3
Additional paid-in capital	711,847	496,195
Accumulated deficit	(404,641)	(238,333)
Accumulated other comprehensive income (loss)	14	(211)
Total stockholders’ equity	307,224	257,654
Total liabilities and stockholders’ equity	$333,169	$274,942

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.